Epilepsy Monitoring Devices Market is Segmented By Product (Wearable Devices, EEG, EMG, MEG, Deep Brain Stimulation Devices, Others), By End User (Hospitals, Ambulatory Surgical Center, Home Care Settings, Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.
Epilepsy Monitoring Devices Market is Predicted to reach at a CAGR of 12.4% during the forecast period (2023-2030). Epilepsy is a central nervous system (neurological) disorder characterized by abnormal brain activity, resulting in seizures or periods of unusual behavior, sensations, and, in some cases, loss of awareness. The rising prevalence of epilepsy in this region and major key players are expected to boost market growth. It is estimated that approximately 1.2 percent of people in the United States have active epilepsy. This equates to approximately 3.4 million people in the United States and more than 65 million worldwide. Furthermore, approximately 1 in every 26 people will develop epilepsy at some point in their lives.
Furthermore, a U.S based company Empatica Inc., develops medical-grade wearables, software, and algorithms for physiological data collection and interpretation. On February 6th, 2018, received FDA approval for Embrace, a seizure-alerting smartwatch that detects generalized tonic-clonic seizures and sends alerts to caregivers. It also keeps track of the patient's activity, stress levels, and overall balance. Hence, increasing FDA approvals and the presence of key players in this region are expected to drive market growth.
Epilepsy Monitoring Devices Market Statistics
Metrics |
Details |
Market CAGR |
12.4% |
Segments Covered |
Product Type, Ulcer Type, By End User, and By Region |
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
Regions Analyzed |
North America, Latin America, Europe, Middle East, Africa, Asia Pacific, and the Rest of the world. |
Major Companies Covered |
FzioMed, Inc., Amniox Medical, Inc., Human Regenerative Technologies, LLC, Amnio Technology, LLC, Derma Sciences, MiMedx Group, Inc, and among other major companies listed in the full report |
To know more insights into the Market, Get Our Sample Brochure
North America region is expected to hold the largest market share in the global epilepsy monitoring devices market
Market Dynamics
The factors expected to drive the global epilepsy monitoring devices market are the increasing technological developments in disease monitoring devices and the increasing prevalence of epilepsy.
The increasing technological developments in disease monitoring devices is expected to drive the market growth in the forecast period
Despite technological advances in devices that monitor the human body, a patient's seizure diary, as it is commonly referred to, remains the only way to record and count epileptic seizures outside of the clinic.
Even accurate seizure recognition is difficult because approximately half of all seizures are unknown to the patient. A new generation of long-term brain monitoring technologies that continuously record brain activity in the clinic or at home is emerging. It has the potential to improve disease management for epilepsy patients significantly. The evolution of engineering technology in the context of epilepsy offers renewed hope for identifying periods when the likelihood of seizure onset is increased and delivering responsive therapy to prevent epileptic events from occurring. For instance, a number of wearable devices that may be capable of detecting seizures, recording seizure data, and alerting caregivers have emerged. Non-invasive wearable sensors that measure accelerometry, photoplethysmography (PPG), electrodermal activity (EDA), electromyography (EMG), and other signals outside of the traditional clinical setting may be able to detect seizure-related changes. Furthermore, user acceptability of such devices must be a top priority to ensure long-term device use.
Limitations of epilepsy monitoring devices are expected to hamper the market growth
Seizure alert devices may be inconvenient for people who live alone or do not want others to check on them. Devices that detect shaking movements usually do not detect focal impaired awareness (previously known as complex partial) seizures. The majority of currently available devices have not been approved by the United States Food and Drug Administration (FDA). The evidence that these devices work to detect seizures is frequently derived from studies conducted in hospital epilepsy monitoring units and, in some cases, at home. The devices do not notify caregivers of any breathing problems or changes in heart rate, which could be critical in SUDEP (Sudden Unexpected Death in Epilepsy). Furthermore, the low specificity of changes in heart rate, low electrode stability, and discomfort with long-term use are some disadvantages of EKG as a seizure detection signal.COVID-19 Impact Analysis
Epilepsy, which affects approximately 50 million people worldwide, is one of the most common neurological diseases and a major cause of disability and mortality, affecting the quality of life and social aspects such as driving or work and necessitating long-term management. Despite the fact that current antiseizure medications effectively control seizures in most patients, one-third of them continue to have seizures (drug-resistant epilepsy). Regular outpatient consultations are thus essential for optimizing antiseizure therapy, managing epilepsy-related behavioural or psychological problems, treating concomitant neurological disorders, conveying psychological support, counselling on family planning, and releasing certifications for a driver's license or fitness work. All of these activities were hampered by the containment measures to deal with the pandemic. The reorganization of healthcare systems inevitably prioritized the management of patients with COVID-19 infection, limiting hospital access for patients with other chronic disorders (including those with epilepsy), and postponing, rescheduling, or even cancelling appointments and examinations.
Furthermore, the industrial lockdown resulted in the halt of management of patients with seizures. Smartphone apps greatly improved communication and information sharing between patients, their families, and caring physicians. Hence, the switch to technology-based management of diseases is expected to drive the demand for seizure monitoring devices due to the covid-19 impact in the forecast period.
Segmentation Analysis
The wearable devices segment is expected to dominate the market growth
Wearable sensing devices are gaining popularity in general and medical applications such as seizure detection. Wearable devices may also allow for more accurate forecasts of seizure likelihood, allowing people with epilepsy to take quick-acting medications or modify their activities in anticipation of an impending seizure. Currently, two FDA and EU-approved wearable sensors detect convulsive seizures. The first, and accelerometry and EDA wrist-worn smartwatch (Empatica Embrace, Boston MA), detects the subject's movements and maintains a Bluetooth link to the subject's smartphone, where an application transmits data and detections to cloud servers and issues caregiver alerts for seizures.
Wearable diagnostic devices have several advantages. The wearable detectors do not take long to set up and do not limit the user's mobility. They have the ability to track information outside of a hospital setting. Wearable seizure detectors are popular among patients and their families because they can improve patient safety, prevent injuries, and increase independence. Approximately 40% of patients are unaware of their seizures, and he added that wearable devices could help these patients identify problems. Furthermore, the devices could detect nocturnal seizures that would otherwise go unnoticed. Hence, the advanatges wearable devices provide is expected to drive this segment's market growth.
Competitive Landscape
The global epilepsy monitoring devices market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are Compumedics Limited, Empatica, Inc., Masimo Corporation, PulseGuard International Ltd., Koninklijke Philips N.V., Medtronic plc, Natus Medical Incorporated, Nihon Kohden Corporation, Possum Ltd.
Empatica Inc.
Overview: Empatica Inc. is a Cambridge, MA-based MIT Media Lab spinoff company that provides AI-enabled tools to advance forecasting, monitoring, research, and treatment. Empatica develops medical-grade wearables, software, and algorithms for physiological data collection and interpretation. The company was founded in 2013.
Product Portfolio: Embrace2 is the world's only FDA-approved wrist-worn epilepsy wearable. It constantly monitors physiological signals and immediately alerts family, friends, and caregivers in the event of a seizure.
Key Developments: On January 11th, 2019, The FDA approved Empatica's seizure-sensing Embrace wristband for children aged six to twenty-one. The device detects tonic-clonic seizures and alerts caregivers, increasing the likelihood that someone will assist the patient in the critical moments following an event.
